Conferences and Events

Precision Medicine World Conference
January 22-24, 2018
Silicon Valley

Dr. Fred Ashbury will present at the 2018 Precision Medicine World Conference in Silicon Valley. Dr. Ashbury will be part of the Clinical Dx Showcase to address cognitive computing in oncology. 

Bundle Blocks 1

Patient Resources - SURVIVEiT®

Our friends at SURVIVEiT have developed patient resources that have been reviewed and approved as "best in class" by Team SURVIVEiT®'s medical and survivor advisory boards.

Visit their cancer resources page to find related medical, financial, and support resources specific to each type of cancer.

SURVIVEiT® is a global community of survivors, doctors, experts, and allies who provide hope, knowledge, and resources crucial to surviving cancer.

After receiving a cancer diagnosis, the most important, urgent question to ask is, "What’s next?" SURVIVEiT® provides the answer.

AI is Changing the Face of Medical Treatment

AI is Changing the Face of Medical Treatment

When you hear the term “artificial intelligence,” you might picture the evil AI overlords from The Matrix that feed on humans, or the androids in Blade Runner relegated to the dangerous task of interplanetary mining. These representations of AI are definitely entertaining, but Hollywood Sci-Fi movies have obscured the practical applications of AI in the real world.

Treating cancer involves a complexity of tests and expert analysis in order to determine the best course of action. Historically, these treatment plans have been developed based on a “one-size-fits-all” approach, without much consideration given to the genomic drivers of the individual’s particular type of cancer.

With new advancements in personalized medicine and cognitive computing, however, treatment therapies can now be tailored to a patient based on their individual genomic profile.

Two companies making improvements in efficiency and decision making in this area are Avera Health and VieCure.  

VieCure and Avera Health Confirm Clinical Validation and System-Wide Implementation of Cognitive Computing Platform

VieCure and Avera Health Confirm Clinical Validation and System-Wide Implementation of Cognitive Computing Platform

VieCure (Greenwood Village, CO) and Avera Health (Sioux Falls, SD) announced today that the VCurePrecision™ platform will be fully implemented across the multi-state cancer system. The platform was developed through a clinical collaboration between the two organizations.

VCurePrecision™ is a cognitive computing platform that generates comprehensive, actionable and patient-specific treatment plans in a matter of seconds. It combines patient-specific diagnostic, surgical and demographic data from the electronic medical record (EMR) with codified expert knowledge to generate personalized treatment plans that comply with nationally respected evidence and the latest clinical guidance.

VieCure Announces Appointment of Howard L. McLeod, PharmD, to the position of Senior Research Advisor in Precision Medicine

VieCure Announces Appointment of Howard L. McLeod, PharmD, to the position of Senior Research Advisor in Precision Medicine

VieCure (Greenwood Village, CO) announced the appointment of Dr. Howard McLeod, to the position of Senior Research Advisor in Precision Medicine.  McLeod will also join the VieCure Clinical Advisory Board.   He is well known to the Precision Medicine community given his leadership responsibilities for the Department of Individualized Cancer Management at the H. Lee Moffitt Cancer Center in Tampa Bay, Florida.

In his role with VieCure, Dr. McLeod will assist in translating research and clinical advances in precision medicine in oncology.  He will help to drive the VieCure technology roadmap and will function as an active ambassador of the Company and the VCurePrecision™ cognitive computing platform at national and international research and clinical symposia.

VieCure Appoints Pradip De, PhD, to the position of Director, Translational Oncology

VieCure Appoints Pradip De, PhD, to the position of Director, Translational Oncology

VieCure Ltd (Greenwood Village, CO) announced the appointment of Dr. Pradip De to the position of Director of Translational Oncology.   Dr. De is the Senior Scientist and Head of Translational Oncology at the Avera Cancer Institute Center for Precision Oncology. He holds the position of Assistant Professor in the Department of Internal Medicine at the University of South Dakota Sanford School of Medicine.

In his role with VieCure, and in light of his superb comprehension of oncogenic signaling pathways, Dr. De will support the development, maintenance, testing and validation of sequence-guided oncology treatment rules. These codified clinical rules enable the translation of patient specific data into actionable knowledge for physicians. VieCure has created a cognitive computing platform that produces actionable and patient-specific treatment plans in real time.

Avera Innovations in the Management of Cancer Conference – A Focus on Breast

Avera Innovations in the Management of Cancer Conference – A Focus on Breast

National and international experts will convene at Avera in Sioux Falls, South Dakota to discuss the latest techniques in breast cancer treatment.

Designed to provide surgeons, radiation oncologists and medical oncologists practice innovations from national and international experts on topics of electron based intra-operative radiation therapy, genomic targeted therapy and oncoplastic surgery techniques.

The conference will focus on the role of genomics, oncoplastic surgery techniques, electron-based intraoperative radiation therapy, neoadjuvant chemotherapy, and the future of surgery and radiation oncology. Attendees will include Surgeons, Radiation Oncologists, Medical Oncologists, and representatives from pharmaceuticals.

The course directors include Julie Reiland, MD, FACS, who specializes in breast cancer treatment and technology at Avera, and Brian Leyland-Jones, MB BS PhD, Vice President of Avera Cancer Institute for Precision Oncology and Vice President of Molecular and Experimental Medicine at Avera.

Precision Medicine World Conference

Precision Medicine World Conference

Dr. Howard McLeod from the Moffitt Cancer Center and Dr. Fred Ashbury, Chief Scientific Officer at VieCure, will host a discussion on the challenges and lessons learned to implement a precision medicine program in oncology at the Precision Medicine World Conference at Duke University on Wednesday, May 24.

Session Synopsis: Precision Medicine (PM) leaders will discuss issues and lessons learned implementing PM programs as well as opportunities for community oncology practices. Topics include: requirements for creating a precision medicine program (personnel, supports); working with sequencing labs;interpreting results; and tools needed to scale and bring genomic-guided therapies to physicians and patients. A presentation of the VCurePrecision™ oncology workbench to facilitate patient-specific genomic-guided treatment plans at point-of-care in real-time will support the discussion.

VieCure and Avera Health Announce a Strategic Collaboration Agreement for Personalized Medicine

VieCure and Avera Health Announce a Strategic Collaboration Agreement for Personalized Medicine

DENVER — (December 15, 2016) — VieCure and Avera Health (Sioux Falls, SD) announced today a first-of-its-kind clinical collaboration in personalized medicine for oncology.  The strategic collaboration will combine Avera’s world leading position in evidence-based knowledge and practical application of genomic-based precision medicine for cancer patients with VieCure’s cognitive computing platform.  Avera’s preeminent molecular cancer knowledge, along with nationally accepted standards of care, will be made accessible, in real time, to patients and treatment teams around the world through the VCurePrecision™ platform.